OMTN, Volume *11*

Supplemental Information

Gene Therapy for Neuropathic Pain through siRNA-IRF5 Gene Delivery with Homing Peptides to Microglia

Tomoya Terashima, Nobuhiro Ogawa, Yuki Nakae, Toshiyuki Sato, Miwako Katagi, Junko Okano, Hiroshi Maegawa, and Hideto Kojima

Figure S1



Figure S1
Electrophoresis of the complexes between MG1 peptide and siRNA-IRF5.
(A) and **(B)** 1.5% Agarose gel after electrophoresis of the complexes between peptides and siRNA. **(A)** MG1-9R peptide and siRNA-IRF5 were mixed and were applied at the combination of the concentration shown at the lower side of each lane. **(B)** MG1 peptide with polyarginine and siRNA-IRF5 were mixed and were applied at the combination of the concentration shown at the lower side of each lane. 0R, 3R, 6R and 9R mean the number of arginine (R) bound with MG1 peptide. Only MG1-0R were conjugated with FITC. FITC, fluorescein isothiocyanate. MG, microglia specific peptides.